Eisai Co., Ltd.｜A human health care company

Certificate of Appreciation from National Department of Health of Papua New Guinea

Eisai's Support towards COVID-19
Eisai's Statement of Commitment for Carbon Neutrality by 2040

Medium- to long-term goals to achieve carbon neutrality
Video Library

Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines
Lymphatic Filariasis Elimination Activities in Kenya

Support for MDA and Provision of Water Tanks

News Release
Latest News
Information

October 18, 2021

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Two Different Types of Cancer
Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Benefit Compared to Sunitinib in CLEAR/KEYNOTE-581 Trial

Positive Opinion Granted for Advanced Endometrial Carcinoma Based on Significant OS and PFS Benefit Compared to Chemotherapy in Study 309/KEYNOTE-775 Trial
September 28, 2021

EISAI INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB (BAN2401) FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
LECANEMAB IS AN ANTI-AMYLOID BETA (Aβ) PROTOFIBRIL ANTIBODY
September 27, 2021

Fully Human Anti-TNFα Monoclonal Antibody HUMIRA® Obtains Additional Approval for High-Dose Regimen of Ulcerative Colitis in Adult Patients and for New Regimen in Pediatric Patients
September 14, 2021

EISAI TO JOIN THE GLOBAL ENVIRONMENTAL INITIATIVE “RE100”
September 14, 2021

EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2021

September 22, 2021

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY
September 22, 2021

IR “Value Creation Report 2021”
August 30, 2021

Sustainability "Eisai was Awarded Certificate of Appreciation by the National Department of Health of Papua New Guinea for Eisai’s Support towards COVID-19"
August 5, 2021

IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2022 [Material, Webcast]”
August 4, 2021

IR “First Quarter Financial Report for the Fiscal Year Ending March 31, 2022”

September 22, 2021

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY
April 19, 2021

Eisai formulates the action plan “Diversity & Inclusion 2021”
December 10, 2020

Notice of Emergence of Employees Infected with the Novel Coronavirus at the Bogor Plant in Indonesia
December 3, 2020

EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY
October 28, 2020

INTERNATIONAL NONPROPRIETARY NAME FOR ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY BAN2401 DECIDED AS LECANEMAB

Eisai at a Glance

Eisai Group Worldwide

About Eisai

About Eisai TOP

Our pursuit of human health care (hhc)

Eisai's hhc Philosophy

Eisai's hhc Philosophy TOP

Investors

Sustainability

Making our medicines available to those who need them

28 countries 2.02 billion tablets

Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of August 2021)

Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries

Sustainability TOP